Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1647 1654 1658 1675
This examiner grants 76% of resolved cases
Julie Ha is a prominent examiner in Tech Center 1600 and Art Unit 1647, having handled 1121 resolved cases. Her allowance rate is 75.6 percent, which is quite high for this tech center. The median days to allowance for her cases is 951, showing a consistent and predictable timeline for successful applications.
The data highlights a significant interview lift of 44.1 percent. This suggests that interviews are an extremely effective tool when working with Ha, providing a substantial boost to the likelihood of allowance. With 1121 resolved cases, her statistics are very robust. Practitioners should strongly consider requesting an interview early in the process to take advantage of this 44.1 percent lift. The combination of a high volume of cases and a strong responsiveness to interviews makes Ha an examiner with whom proactive communication is highly rewarded.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18011363 | COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING COGNITIVE DYSFUNCTION DISEASE, COMPRISING PEPTIDE HAVING SYNAPTIC PLASTICITY CONTROL FUNCTION | Final Rejection | UIF (University Industry Foundation), Yonsei University |
| 18292207 | BARRIER FUNCTION PRESERVING PEPTIDES FOR MEMBRANES | Non-Final OA | The Regents of the University of California |
| 18518981 | Treatment of Glaucoma by Neuroprotection | Non-Final OA | The Regents of the University of California |
| 17442831 | COMPOSITIONS AND METHODS OF TREATING AND PREVENTING SYSTEMIC COMPLICATIONS OF ACUTE ILLNESS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17795797 | THERAPEUTIC USES OF DULAGLUTIDE | Non-Final OA | Eli Lilly and Company |
| 18726124 | POLYPEPTIDE AND APPLICATION THEREOF IN PREPARATION OF ANTI-FIBROSIS DRUG | Non-Final OA | Zhejiang University |
| 18280186 | APPLICATION OF APOPTOSIS INHIBITOR 5 (API5) FOR EPITHELIAL RESTITUTION | Non-Final OA | New York University |
| 18028372 | HAIR GROWTH AGENT | Non-Final OA | RIKEN |
| 18620631 | PD-1 AGONIST | Non-Final OA | GEORGE MASON UNIVERSITY |
| 17759634 | ALLERGEN PROTECTION FOR THE SKIN | Final Rejection | BEIERSDORF AG |
| 18334732 | MACROCYCLIC PEPTIDES | Non-Final OA | UNIVERSITY OF NOTRE DAME DU LAC |
| 18724295 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | Non-Final OA | CAREGEN CO., LTD. |
| 17908532 | COMPOUNDS FOR USE IN AUTOIMMUNE CONDITIONS | Final Rejection | PHARMA MAR, S.A. |
| 17920598 | LACTIC ACID BACTERIA GROWTH PROMOTER | Final Rejection | Asahi Group Holdings, Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy